Search This Blog

Friday, November 8, 2024

Harris campaign election-eve concerts said to cost up to $20M; staff, vendors fear won’t be paid

 You live, you learn.

Finger-pointing has erupted over the Kamala Harris campaign blowing up to $20 million on swing-state concerts Monday night, hours before the VP’s spectacular election loss to Donald Trump — prompting concern that everyday staff and vendors won’t get paid amid reports the campaign is in debt by the same amount.

Members of the defeated Harris team tell The Post that the concerts had a ruinous effect on the Democratic campaign’s coffers and that fact was no secret — with one planned performance by ’90s alt-rock goddess Alanis Morissette getting scrapped to save money.

The seven swing-state concerts on election eve featured performances by Jon Bon Jovi in Detroit, Christina Aguilera in Las Vegas, Katy Perry in Pittsburgh and Lady Gaga in Philadelphia — with 2 Chainz joining Harris on Nov. 2, three days before the election, for an eighth concert in Atlanta.

Lady Gaga performs at a rally for Vice President Kamala Harris Monday in Philadelphia.AP
Jon Bon Jovi performs at a rally Monday featuring Minnesota Gov. Tim Walz in downtown Detroit.Middle East Images/AFP via Getty Images
Two sources said that Obama campaign alum Stephanie Cutter pushed the concert concept as a way to woo lower-propensity voters to the polls.

While the performers donated their time and talent, the sets still required an immense commitment of manpower and financial resources.

Cutter’s plan was supported by fellow Obama alum David Plouffe, one source said.

Harris added Cutter and Plouffe to her campaign shortly after replacing President Biden atop the party’s ticket in July, generating internal tensions with the existing Biden campaign team as the newcomers sought to replay the 44th president’s successful 2008 campaign.

Christina Aguilera performs during the Harris-Walz election eve campaign rally Monday in Las Vegas.Paul Citone/imageSPACE/Shutterstock
Oprah Winfrey stole the show — and most of the attention — for the concerts by claiming Donald Trump would impose a dictatorship.AP

Harris-Walz campaign chairwoman Jen O’Malley Dillon ultimately approved the get-out-the-vote concert plans, but has since told colleagues — in response to significant internal criticism — that she didn’t want to do them and sat on the idea for weeks, one source told The Post.

If that was the case, another source pointed out, then O’Malley Dillon’s waffling led to increased production costs because “putting [concerts] together last minute makes [them] cost twice as much.”

Internal critics also questioned the role of campaign operations chief Dana Rosenzweig, whom one source noted controlled the Harris-Walz purse strings and was responsible for raising any financial concerns.

“They said they were ‘spending to zero.’ I guess they overshot zero,” quipped one source.

As it happened, the events hardly made a splash in the news cycle — with the exception of the Philadelphia rally, where Oprah Winfrey stole the show by claiming that Trump winning might mean “we will not have the opportunity to cast a ballot again.”

Voters in each of the seven swing states turned out the next day to elect Trump, the former president and Republican nominee.

Harris attended the Philadelphia event — before losing the presidential election the next day.Getty Images
Katy Perry performed during a campaign rally for Harris in Pittsburgh Monday.AP
Sugarland performed at a Harris campaign concert in Raleigh, NC.Anadolu via Getty Images

“They had huge advance teams for these concerts, like 40-60 people in some cities,” said an insider who told The Post that they are concerned about the financial impact on people who worked to elect Harris.

“I’m sure vendors will start to get upset soon,” the source added, noting that staff payments do not seem to be impacted so far, though expense reimbursements are still pending.

In the week before Election Day, as campaign bosses became aware that nearly all of their more than $1 billion war chest was gone, there were efforts to scale back concert costs — which were expected to run between $15 million and $20 million, but in some cases experienced overruns.

“They definitely knew the budget crunch at the end because they cut talent from some cities because of cost,” the source said, adding that Morissette’s show got the ax just two days before the scheduled performance.

2 Chainz performed at Harris’ Atlanta concert three days before the election.EDWARD M PIO RODA/EPA-EFE/Shutterstock

A different Harris campaign source said that finance staff currently are in the process of reconciling the balance sheets and that nobody has been stiffed. 

A third source called the events “a real misuse of funds that could have been better spent on ads laying out economic policies” to voters angered about inflation and high interest rates.

“It didn’t matter to have a bunch of celebrities talking to no one because one, 75 million people already voted and two, people were concerned about their own financial issues, not Oprah telling them America won’t exist,” this source said.

Despite the enormous fundraising haul in the 107-day campaign spring, the Harris campaign ended the race at least $20 million in debt, Politico reported Thursday. Donation webpages remain active in the apparent hope of an after-the-fact trickle of funds to close the gap.

Spokespeople for the Harris campaign and Morissette did not respond to The Post’s requests for comment.

Vice President Kamala Harris greets Lady Gaga and her husband Michael Polansky at a campaign rally outside the Philadelphia Museum of Art, Monday, Nov. 4, 2024, in Philadelphia.

https://nypost.com/2024/11/08/us-news/kamala-harris-campaigns-election-eve-concerts-said-to-cost-up-to-20m-as-rank-and-file-staff-vendors-fear-they-wont-be-paid/

Autolus AUCATZYL OKd for relapsed/refractory B-cell acute lymphoblastic leukemia

 

  • AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
  • Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
  • Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release

Management will host a conference call and webcast on November 11 at 8:30 am EST/1:30 pm BST to discuss the AUCATZYL approval. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

https://www.globenewswire.com/news-release/2024/11/08/2977884/0/en/Autolus-Therapeutics-Announces-FDA-Approval-of-AUCATZYL-obecabtagene-autoleucel-obe-cel-for-adults-with-relapsed-refractory-B-cell-acute-lymphoblastic-leukemia-r-r-B-ALL.html

McCormick sues to challenge provisional ballots in Philadelphia

 Pennsylvania Republican Senate candidate David McCormick filed two lawsuits challenging provisional ballots in Philadelphia, signaling he is prepared to take his fight to the Supreme Court. 

McCormick declared victory after The Associated Press projected Thursday that he beat incumbent Sen. Bob Casey (D) in the key race. Decision Desk HQ, The Hill’s election data partner, has not yet called the race.

McCormick’s lawyers said Philadelphia plans to adjudicate between 15,000 and 20,000 provisional ballots and that his campaign intends to challenge “large groups” of them for not complying with statutory requirements.

The Republican asked for court permission to challenge batches of ballots collectively rather than fighting each one individually, citing a need for efficiency. McCormick also asked that election officials only be allowed to adjudicate provisional ballots in the presence of a Republican Party representative.

“Plaintiff is concerned that the sheer number of provisional ballots will overwhelm the capacity for individual challenges, creating an impractical burden that risks errors or inconsistencies in the adjudication process,” McCormick’s lawyers wrote in court filings. 

“Without the ability to make global challenges, Plaintiffs fear that potentially non-compliant ballots may be improperly counted, compromising the fairness and integrity of the election,” they continued. 

Decision Desk HQ reports McCormick leads Casey by 0.5 percentage points, the edge of the threshold that triggers an automatic recount. Casey’s campaign has not conceded and said Thursday that the “count in Pennsylvania is still continuing.”

“The number of provisional ballots expected from areas that favor Senator Casey, like Philadelphia and its suburbs, is further proof that this race is too close to be called,” Maddy McDaniel, Casey’s campaign spokesperson, said in a statement. “As the McCormick campaign admitted in their own lawsuit this morning, the counting of these ballots could have an ‘impact on the outcome of the election.’ With more than 100,000 ballots still left to count, we will continue to make sure Pennsylvanians’ voices are heard.”

The Hill has reached out to Philadelphia’s elections board for comment.

Provisional ballots in Pennsylvania had been the subject of significant litigation before the election.

Pennsylvania’s top court ruled 4-3 that voters who submit deficient mail ballots — such as ones not including an inner, secrecy envelope — were entitled to an in-person do-over by casting a provisional ballot at their polling place. Republicans have argued the additional option runs afoul of state law. 

The Supreme Court refused Republicans’ request to halt the decision before the election. But three conservative justices issued a statement making clear they weren’t rejecting Republicans’ underlying claim that the state court was usurping the Pennsylvania Legislature’s constitutional authority in setting voting rules.

McCormick’s new lawsuits set up the possibility the dispute, which is rooted in the “independent state legislature theory,” could return to the justices. The Senate candidate’s lawyers wrote in court filings that the litigation “is ripe for appeal to the United States Supreme Court.”

They asked that the challenged ballots be sequestered until the high court resolves the legal battle. 

The lawsuits come as election officials begin their canvass of provisional ballots, which under state law does not commence until the Friday following Election Day. On Thursday, Philadelphia officials said they were still tallying how many provisional ballots were received. 

Pennsylvania Secretary of State Al Schmidt (R) estimated Thursday there were at least 100,000 ballots remaining statewide, including provisional, military, overseas and Election Day votes. 

“We urge patience as election workers continue to do this important work, especially in contests where the margins are very close,” Schmidt said. 

https://thehill.com/regulation/court-battles/4980694-mccormick-lawsuits-provisional-ballots-pennsylvania/

Mason Capital: Corporate Governance Failures, Shareholder Value Destruction by Grifols Board

 Sends Letter to Board Detailing Board’s Conflicts of Interest and History of Poor Capital Allocation

Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value

Believes Rumored Brookfield Transaction Substantially Undervalues Grifols

Text of the letter follows:

November 8, 2024

Grifols, S.A.
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - SPAIN

Dear Grifols Board Members and Shareholders;

Mason Capital is a significant Grifols shareholder, controlling ~2.1% of the Class A shares. The rumored Brookfield transaction is the product of improper corporate governance by a conflicted Board with a history of poor capital allocation. While the family and its related directors currently have de facto Board control, it is with only ~31% of the Class A voting shares. The remaining 69% can permanently fix the corporate governance failings at Grifols and unlock tremendous value by doing so. Brookfield is not needed.

The current board has a long history of poor capital allocation. As illustrated below, every large (€1bn+) transaction since 2014 has destroyed shareholder value. The transactions were 100% debt financed, resulting in approximately €4.5 billion of additional debt on Grifols’ balance sheet while only adding €136 million of economic EBITDA (measured for the trailing twelve-month period ended September 30, 2024) – an implied multiple >32x EBITDA. By comparison, Grifols’ stock currently trades for ~8.5x 2025E EBITDA per consensus estimates.

https://www.businesswire.com/news/home/20241107873955/en

Ivermectin Found to Have Dual Effect in Rosacea

 

TOPLINE: 

Topical ivermectin treatment was found to increase Staphylococcus epidermidis on the skin of patients with rosacea, in addition to reducing density of Demodex, in a small study. 

METHODOLOGY:

  • In this single-center, open label study, 10 adults (mean age, 66.4 years) with papulopustular rosacea were treated with 1% ivermectin cream daily for 12 weeks.
  • Skin swabs from lesional and nonlesional sites were collected at baseline and after 3 months of treatment to assess changes in the bacterial microbiome and the density of Demodex mites.
  • The average baseline total papule count was 26.9, and the Clinician’s Erythema Assessment (CEA) score was 2 (average value on a scale of 0-4 from five locations on the face).
  • For comparison, baseline swabs were taken from 10 healthy age-matched individuals.

TAKEAWAY:

  • The density of Demodex mites was significantly reduced on lesional skin (P = .002) with topical ivermectin, which has anthelmintic effects against Demodex and is an effective treatment for rosacea.
  • The absolute abundance of S. epidermidis increased after ivermectin treatment on lesional skin (P = .039), while no changes were seen in Cutibacterium acnes.
  • No changes were noted on nonlesional skin in the patients with rosacea.
  • Topical ivermectin also reduced the number of papules and CEA scores (both = .002) in individuals with rosacea.

IN PRACTICE:

" Treatment with topical ivermectin may improve the symptoms of rosacea through modulation of the skin microbiome beyond decreasing Demodex," the authors concluded. "The results of this study,” they added, “provide valuable insights into the intricacies of the cutaneous microbiome in the pathophysiology of rosacea and highlight the potential therapeutic interventions targeting the skin microbiome."

SOURCE:

The study was led by Teruaki Nakatsuji, PhD, of the department of dermatology, University of California, San Diego, La Jolla, California. It was published online on October 29 in the Journal of Investigative Dermatology.

LIMITATIONS: 

The small sample size of 10 patients with rosacea limits the generalizability of the findings, and the study's open-label design may introduce bias in the clinical assessments. Further research with larger sample sizes and randomized controlled trials is needed to confirm these findings.

DISCLOSURES:

This work was funded by a grant from the National Rosacea Society. One author disclosed being the cofounder and consultant, with equity interest in MatriSys Bioscience. The other authors reported no competing interests.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

https://www.medscape.com/viewarticle/ivermectin-found-have-dual-effect-rosacea-2024a1000kgd